8-K filed May 17, 2024, 7:59 PM ET ticker CYTK CIK 0001061983

other material confidence high sentiment neutral materiality 0.25

Cytokinetics director Smith resigns; stockholders approve 300K-share ESPP increase

CYTOKINETICS INC

Sandford D. Smith resigned from the board effective before the 2024 annual meeting, not due to any disagreement.
Stockholders approved amendment to ESPP increasing authorized shares by 300,000 to total 1,159,879 shares.
Robert I. Blum and Robert A. Harrington elected as Class II directors for three-year terms.
Ernst & Young LLP ratified as independent auditor for 2024; say-on-pay proposal passed advisory vote.
Approximately 91.97% of eligible shares (96,181,650 votes) represented at the meeting, forming a quorum.

item 5.02 item 5.07 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-24-061275
form_type: 8-K
ticker: CYTK
cik: 0001061983
company_name: CYTOKINETICS INC
filed_at: 2024-05-17T23:59:59+00:00
discovered_at: 2026-05-14T18:03:17.131433+00:00
generated_at: 2026-06-01T14:25:39.155369+00:00
sec_items: ["5.02", "5.07", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-24-061275
json_url: https://secwatch.observer/filing/0000950170-24-061275.json
markdown_url: https://secwatch.observer/filing/0000950170-24-061275.md
text_url: https://secwatch.observer/filing/0000950170-24-061275.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/cytk-20240515.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sandford D. Smith

Director

CYTK · CYTOKINETICS INC

Effective: 2024-05-15
Filed: May 17, 2024, 7:59 PM ET

On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).

Source-grounded claims

50c4892c53

Sandford D. Smith resigned as Director at CYTOKINETICS INC.

On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

23a54c37e0fc9223e2d8f4b0385ea972256260f0

CYTOKINETICS INC shareholders approved Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock..

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

71bd5ff0eeb9ed6369f5b0c61ccb56de1c471bab

CYTOKINETICS INC shareholders approved Election of Two Class II Directors.

Proposal 1: Election of Two Class II Directors The stockholders elected Robert I. Blum and Robert A. Harrington, M.D. as Class II Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows: Name For Withheld Broker Robert I. Blum 87,317,169 2,214,926 6,649,555 Robert A. Harrington, M.D. 78,347,186 11,184,909 6,649,555

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

a3fa0bcb4a7f6d274bbba30f3db55ecc3ab03866

CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation.

Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the 2024 Proxy Statement. The votes were as follows: For Against Abstain Broker Non-Vote 85,814,395 2,927,007 790,693 6,649,555

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

bb55d5420a0729e224349745cd2407a903645761

CYTOKINETICS INC shareholders approved Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-12-31 meeting.

Proposal 3: Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 The stockholders ratified the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were as follows: For Against Abstain 95,957,265 97,750 126,635

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

Comparable filings

SYRE

Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns

Spyre Therapeutics, Inc. May 29, 2026, 4:45 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).

Comparable filing

In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.

Filing page SEC filing

MPT

MPT shareholders elect all directors, approve say-on-pay and equity plan with notable opposition

MEDICAL PROPERTIES TRUST INC June 1, 2026, 4:55 PM ET other_material Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Comparable filing

Proposal 2: The ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026: For: Against: Abstensions: Broker Non-Votes: 459,883,831 6,189,396 2,613,330 —

Filing page SEC filing

LODE

Comstock holds AGM; all director nominees elected, auditor and equity plan approved

Comstock Inc. June 1, 2026, 4:15 PM ET other_material Items 5.07, 7.01, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Comparable filing

4. Vote on Comstock Inc. 2026 Equity Incentive Plan. The stockholders approved the Comstock Inc. 2026 Equity Incentive Plan as set forth below. Voted For Voted Against Abstain Broker Non-Votes 25,069,375 1,393,479 1,194,028 21,410,649

Filing page SEC filing

HNVR

Shareholders elect three directors, approve equity plan, ratify auditor at annual meeting

Hanover Bancorp, Inc. /MD June 1, 2026, 4:00 PM ET other_material Items 5.02, 5.07

same fact type: shareholder_vote same SEC item: 5.02, 5.07 same event type: other_material similar materiality

This filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Comparable filing

2. The Hanover Bancorp, Inc. 2026 Equity Incentive Plan was approved by the shareholders by the following vote: FOR AGAINST ABSTAIN 4,755,228 27,522 43,684 There were 903,723 broker non-votes on the proposal.

Filing page SEC filing

VOYG

Stockholders approve redomestication from Delaware to Texas at annual meeting

Voyager Technologies, Inc./DE June 1, 2026, 4:49 PM ET other_material Items 5.07

same fact type: shareholder_vote same SEC item: 5.07 same event type: other_material similar materiality

This filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Comparable filing

The results of the vote were as follows: For Against Abstain Broker Non-Votes 98,600,810 8,426,781 98,301 13,043,864 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing page SEC filing

TDAY

Annual meeting elects directors, ratifies auditor; four governance proposals fail to meet 80% supermajority threshold

USA TODAY Co., Inc. June 1, 2026, 4:31 PM ET other_material Items 5.07

same fact type: shareholder_vote same SEC item: 5.07 same event type: other_material similar materiality

This filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Comparable filing

Proposal 1 . The Company's stockholders elected the following eight director nominees to serve until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.

Filing page SEC filing

NSTS

NSTS Bancorp annual meeting: directors elected, auditor ratified

NSTS Bancorp, Inc. June 1, 2026, 4:16 PM ET other_material Items 5.07

same fact type: shareholder_vote same SEC item: 5.07 same event type: other_material similar materiality

This filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Comparable filing

The ratification of the appointment of Plante & Moran, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026: FOR AGAINST ABSTAIN BROKER NON-VOTES 3,708,805 207,145 85,662 0

Filing page SEC filing

CBNK

Capital Bancorp shareholders elect all director nominees, approve say-on-pay, ratify auditor

Capital Bancorp Inc June 1, 2026, 4:05 PM ET other_material Items 5.07

same fact type: shareholder_vote same SEC item: 5.07 same event type: other_material similar materiality

This filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Comparable filing

Proposal 3 – The ratification of the appointment of Elliott Davis, PLLC as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN BROKER NON-VOTES 13,466,844 198,796 9,223 0

Filing page SEC filing

Source: SEC EDGAR

accession 0000950170-24-061275

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.